Miller M L
University of Texas Health Science Center, San Antonio.
Curr Opin Rheumatol. 1991 Oct;3(5):803-8. doi: 10.1097/00002281-199110000-00009.
Reports on a variety of therapies for systemic lupus erythematosus have been published over the past year. Most of these are single case reports or open studies. As reported last year in this journal, the potential uses of intravenous gamma globulin and plasmapheresis continue to be explored. The use of cyclophosphamide for nonrenal manifestations follows studies last year of its use for lupus nephritis. No major double-blind studies of therapy for lupus nephritis were published; however, the course of lupus patients receiving dialysis or grafts was the subject of three interesting studies. An interesting study on the ability of hydroxychloroquine to prevent disease exacerbations was also published. In summary, the reports of therapy over the past year represent variations on themes. The use of new agents will most likely be based on improvements in our understanding of the pathogenesis of systemic lupus erythematosus.
过去一年里发表了各种关于系统性红斑狼疮治疗方法的报告。其中大多数是单病例报告或开放性研究。正如去年本刊所报道的，静脉注射丙种球蛋白和血浆置换的潜在用途仍在探索中。环磷酰胺用于非肾脏表现的治疗是基于去年其用于狼疮性肾炎的研究。去年没有发表关于狼疮性肾炎治疗的大型双盲研究；然而，接受透析或移植的狼疮患者的病程是三项有趣研究的主题。还发表了一项关于羟氯喹预防疾病加重能力的有趣研究。总之，过去一年的治疗报告都是同一主题的不同变体。新药物的使用很可能基于我们对系统性红斑狼疮发病机制理解的改进。
